104 related articles for article (PubMed ID: 7576982)
1. Exposure and schedule dependency of etoposide in neuroblastoma and leukaemia cells in vitro.
Lowis SP; Newell DR; Pearson AD
Eur J Cancer; 1995; 31A(4):622-6. PubMed ID: 7576982
[TBL] [Abstract][Full Text] [Related]
2. The schedule-dependent effects of etoposide in leukaemic cell lines: a function of concentration and duration.
Liu WM; Joel SP
Cancer Chemother Pharmacol; 2003 Apr; 51(4):291-6. PubMed ID: 12721756
[TBL] [Abstract][Full Text] [Related]
3. Etoposide toxicity on human neuroblastoma cells in vitro is enhanced by preceeding hyperthermia.
Van Heek-Romanowski R; Pütter S; Trarbach T; Kremens B
Med Pediatr Oncol; 2001 Jan; 36(1):197-8. PubMed ID: 11464882
[TBL] [Abstract][Full Text] [Related]
4. Low dose of arsenic trioxide inhibits multidrug resistant-related P-glycoprotein expression in human neuroblastoma cell line.
Liu L; Li Y; Xiong X; Qi K; Zhang C; Fang J; Guo H
Int J Oncol; 2016 Dec; 49(6):2319-2330. PubMed ID: 27840903
[TBL] [Abstract][Full Text] [Related]
5. Relationship between cytotoxicity and site-specific DNA recombination after in vitro exposure of leukemia cells to etoposide.
Chen CL; Fuscoe JC; Liu Q; Pui CH; Mahmoud HH; Relling MV
J Natl Cancer Inst; 1996 Dec; 88(24):1840-7. PubMed ID: 8961974
[TBL] [Abstract][Full Text] [Related]
6. Rationally designed hydrolytically activated etoposide prodrugs, a novel strategy for the treatment of neuroblastoma.
Lange B; Schroeder U; Huebener N; Jikai J; Wenkel J; Strandsby A; Wrasidlo W; Gaedicke G; Lode HN
Cancer Lett; 2003 Jul; 197(1-2):225-30. PubMed ID: 12880986
[TBL] [Abstract][Full Text] [Related]
7. Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy.
Keshelava N; Seeger RC; Groshen S; Reynolds CP
Cancer Res; 1998 Dec; 58(23):5396-405. PubMed ID: 9850071
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo evaluation of etoposide - silk wafers for neuroblastoma treatment.
Yavuz B; Zeki J; Coburn JM; Ikegaki N; Levitin D; Kaplan DL; Chiu B
J Control Release; 2018 Sep; 285():162-171. PubMed ID: 30018030
[TBL] [Abstract][Full Text] [Related]
9. Trifluoperazine modulation of resistance to the topoisomerase II inhibitor etoposide in doxorubicin resistant L1210 murine leukemia cells.
Kamath N; Grabowski D; Ford J; Drake F; Kerrigan D; Pommier Y; Ganapathi R
Cancer Commun; 1991 Feb; 3(2):37-44. PubMed ID: 1995027
[TBL] [Abstract][Full Text] [Related]
10. A method for determining schedule dependency in tissue culture.
Wampler GL; Carter WH; Campbell ED; Keefe PA
J Biopharm Stat; 1991; 1(2):261-86. PubMed ID: 1668959
[TBL] [Abstract][Full Text] [Related]
11. Purging of the neuroblastoma stem cell compartment and tumor regression on exposure to hypoxia or cytotoxic treatment.
Marzi I; D'Amico M; Biagiotti T; Giunti S; Carbone MV; Fredducci D; Wanke E; Olivotto M
Cancer Res; 2007 Mar; 67(6):2402-7. PubMed ID: 17363556
[TBL] [Abstract][Full Text] [Related]
12. Neuroblastoma directed therapy by a rational prodrug design of etoposide as a substrate for tyrosine hydroxylase.
Jikai J; Shamis M; Huebener N; Schroeder U; Wrasidlo W; Wenkel J; Lange B; Gaedicke G; Shabat D; Lode HN
Cancer Lett; 2003 Jul; 197(1-2):219-24. PubMed ID: 12880985
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxicity of paclitaxel and docetaxel in human neuroblastoma cell lines.
Riccardi A; Servidei T; Tornesello A; Puggioni P; Mastrangelo S; Rumi C; Riccardi R
Eur J Cancer; 1995; 31A(4):494-9. PubMed ID: 7576952
[TBL] [Abstract][Full Text] [Related]
14. Calmodulin inhibitor trifluoperazine in combination with doxorubicin induces the selection of tumour cells with the multidrug resistant phenotype.
Kamath N; Grabowski D; Ford J; Ganapathi R
Br J Cancer; 1993 Jun; 67(6):1203-8. PubMed ID: 8099806
[TBL] [Abstract][Full Text] [Related]
15. Low dose--high dose: what is the right dose? Pharmacokinetic modeling of etoposide.
Würthwein G; Boos J
Cancer Chemother Pharmacol; 2002 Apr; 49(4):303-8. PubMed ID: 11914910
[TBL] [Abstract][Full Text] [Related]
16. Sequence dependent synergistic cytotoxicity between etoposide and fluoropyrimidines.
Damon LE; Christensen S; Rochlitz C; Cadman EC
Anticancer Res; 1989; 9(6):1761-7. PubMed ID: 2534035
[TBL] [Abstract][Full Text] [Related]
17. Reciprocal potentiation of the antitumoral activities of FK866, an inhibitor of nicotinamide phosphoribosyltransferase, and etoposide or cisplatin in neuroblastoma cells.
Travelli C; Drago V; Maldi E; Kaludercic N; Galli U; Boldorini R; Di Lisa F; Tron GC; Canonico PL; Genazzani AA
J Pharmacol Exp Ther; 2011 Sep; 338(3):829-40. PubMed ID: 21685314
[TBL] [Abstract][Full Text] [Related]
18. Concentration- and time-dependent cytostatic effects of methotrexate and etoposide on L1210 leukemic cells in vitro demonstrated by a new microperfusion method.
Gimmel S; Maurer HR
Anticancer Res; 1994; 14(1A):129-35. PubMed ID: 8166439
[TBL] [Abstract][Full Text] [Related]
19. Impact of histone deacetylase inhibitor valproic acid on the anticancer effect of etoposide on neuroblastoma cells.
Groh T; Hrabeta J; Poljakova J; Eckschlager T; Stiborova M
Neuro Endocrinol Lett; 2012; 33 Suppl 3():16-24. PubMed ID: 23353839
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of anticancer drug schedule dependency using an in vitro human tumor clonogenic assay.
Ludwig R; Alberts DS; Miller TP; Salmon SE
Cancer Chemother Pharmacol; 1984; 12(3):135-41. PubMed ID: 6705130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
